Search results
Results from the WOW.Com Content Network
Calcitonin, as salmon calcitonin (sCT), is available in the pharmaceutical market as an injectable preparation for intravenous, intramuscular or subcutaneous application. Noninvasive sCT preparation as a nasal spray is commercially produced and received US FDA approval under the proprietary name Miacalcin® in 1975 for the treatment of ...
Calcitonin can be used therapeutically for the treatment of hypercalcemia or osteoporosis. ... and nasal spray dosage forms of the salmon calcitonin, noninvasive oral ...
Additionally, there is question of the overall efficacy of calcitonin-containing nasal sprays. A phase III trial found no difference between placebo and nasal calcitonin sprays on lumbar bone mineral density in osteoporosis. [34] It did find a significant increase in bone mineral density with oral calcitonin.
An experimental nasal spray has helped clear toxic protein buildups in the brains of mouse models of Alzheimer's. Its developers believe the spray may help delay Alzheimer's by at least a decade.
Intranasal calcitonin, calcitonin-salmon, is used to treat hypercalcaemia arising out of malignancy, Paget's disease of bone, post menopausal and steroid induced osteoporosis, phantom limb pain and other metabolic bone abnormalities, available as Rockbone, Fortical and Miacalcin Nasal Spray.
Nasal sprays are already being used to treat or prevent a number of ailments, such as: Allergies: Seasonal-allergy-fighting nasal sprays may be the first thing a lot of people turn to, ...
Nasal sprays are used to deliver medications locally in the nasal cavities or systemically. They are used locally for conditions such as nasal congestion and allergic rhinitis . In some situations, the nasal delivery route is preferred for systemic therapy because it provides an agreeable alternative to injection or pills.
In 2018, three CGRP blockers were approved by the FDA for the prevention of migraine: erenumab; fremanezumab; and galcanezumab.. The calcitonin gene-related peptide (CGRP) is a therapeutic target in migraine because of its hypothesized role in mediating trigeminovascular pain transmission and the vasodilatory component of neurogenic inflammation (see "Pathophysiology, clinical manifestations ...